SCHEMBL2133223

SCHEMBL2133223

O=C(c1ccc(-c2ccc(Cl)c(Cl)c2)cc1)N1CC(N[C@H]2CCN(C(=O)c3ccccc3)C2)C1

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 6/20 0.47
PTPN2 P17706 1/20 0.47
PTPN1 P18031 1/20 0.47
EPHX1 P07099 1/20 0.47
SMO Q99835 1/20 0.45
TACR2 P21452 1/20 0.45
TACR1 P25103 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
SPR P35270 1/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2129559 0.88 EPHX1 (0.56) MGLLPTPN2PTPN1EPHX1SMN1; SMN2
SCHEMBL2130909 0.88 MGLL (0.60) MGLLPTPN2PTPN1EPHX1SMN1; SMN2
SCHEMBL2131338 0.88 MGLL (0.50) MGLLPTPN2PTPN1EPHX1SMN1; SMN2
SCHEMBL2132004 0.82 SMN1; SMN2 (0.54) MGLLPTPN2PTPN1EPHX1SMN1; SMN2
SCHEMBL2130059 0.81 HSD11B1 (0.62) PTPN1EPHX1SMN1; SMN2ALDH1A1LMNA
SCHEMBL2134021 0.81 ABL1 (0.53) MGLLSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL2132024 0.81 ADAMTS7 (0.54) MGLL
SCHEMBL2721726 0.81 ADAMTS7 (0.54) MGLL
SCHEMBL2731835 0.81 MCHR1 (0.54) EPHX1SMOMEN1KMT2A
SCHEMBL2131274 0.81 MCHR1 (0.54) EPHX1SMOMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748417-B2 Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2014-06-10 US claimed
US-8575363-B2 Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2013-11-05 US claimed
US-20130196970-A1 AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA, NV (BE) 2013-08-01 US claimed
US-20120101081-A1 AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA, NV (BE) 2012-04-26 US claimed
US-8748417-B2 Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2014-06-10 US disclosed
US-8575363-B2 Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2013-11-05 US disclosed
US-20130196970-A1 AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA, NV (BE) 2013-08-01 US disclosed
US-20120101081-A1 AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA, NV (BE) 2012-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130196970-A1 AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, MGLL MGLL 3/4885PTPN2 1186/4885PTPN1 982/4885
US-20120101081-A1 AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, MGLL MGLL 3/4885PTPN2 1186/4885PTPN1 982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.